title: Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
abstract: The common properties of broadly cross-reactive HIV-1 neutralization antibodies found in certain HIV-1-infected individuals holds significant value for understanding natural and vaccine-mediated anti-HIV immunity. Recent efforts have addressed this question by deriving neutralizing monoclonal anti-envelope antibodies from memory B cell pools of selected subjects. However, it has been more difficult to identify whether broadly neutralizing antibodies circulating in plasma possess shared characteristics among individuals. To address this question, we used affinity chromatography and isoelectric focusing to fractionate plasma immunoglobulin from 10 HIV-1-infected subjects (5 subjects with broad HIV-1 neutralizing activity and 5 controls). We find that plasma neutralizing activity typically partitions into at least two subsets of antibodies. Antibodies with restricted neutralization breadth have relatively neutral isoelectric points and preferentially bind to envelope monomers and trimers versus core antigens from which variable loops and other domains have been deleted. In comparison, broadly neutralizing antibodies account for a minor fraction of the total anti-envelope response. They are consistently distinguished by more basic isoelectric points and specificity for epitopes shared by monomeric gp120, gp120 core, or CD4-induced structures. Such biochemical properties might be exploited to reliably predict or produce broad anti-HIV immunity.
authors.affiliation: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Mohammad M
authors.initials: MM
authors.lastname: Sajadi
authors.forename: George K
authors.initials: GK
authors.lastname: Lewis
authors.forename: Michael S
authors.initials: MS
authors.lastname: Seaman
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Guan
authors.forename: Robert R
authors.initials: RR
authors.lastname: Redfield
authors.forename: Anthony L
authors.initials: AL
authors.lastname: DeVico
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000097:blood / Q000737:chemistry* / Q000276:immunology*; D000918:Antibody Specificity; D018791:CD4 Lymphocyte Count; D003429:Cross Reactions / Q000276:immunology; D005260:Female; D015483:HIV Antibodies / Q000097:blood / Q000737:chemistry* / Q000276:immunology*; D015658:HIV Infections / Q000097:blood / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification / Q000276:immunology; D007135:Immunoglobulin Variable Region / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D019562:Viral Load
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D007074:Immunoglobulin G; D007135:Immunoglobulin Variable Region